Placeholder canvas

March 2023 Top Biopharma Deal: OncoC4 – BioNTech for ONC-392 for Solid Tumors and NSCLC

Apr 3, 2023 | Deal of the Month, Partnership Deals

March 2023 Top Biopharma Deal Upfront
OncoC4 co-development and commercialization deal with BioNTech for ONC-392

Highlighted Deal Financial Comps

Date Announced:

March 20, 2023

Total Deal Value:

$200M + Mst

Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

Undisclosed dev., reg., and sales milestones


Undisclosed tiered double-digit royalties

Cost & Profit Split:

50% development cost split

Deal Synopsis

The Asset:

OncoC4's ONC-392 anti-CTLA-4 monoclonal antibody candidate in Phase II as monotherapy or in combination with anti-PD1 in various solid tumor indications, including immunotherapy-resistant non-small cell lung cancer (NSCLC).

Deal Structure:

Development and Commercial License

Partnership Features:

Co-Development, Shared Cost

Deal Details:

  • OncoC4 granted BioNTech exclusive, worldwide rights to co-develop and commercialize OncoC4’s ONC-392, an anti-CTLA-4 mAb as a monotherapy and in combination with anti-PD-(L)-1 antibodies for the treatment of solid tumors, including NSCLC.
  • OncoC4 and BioNTech will equally share the development costs while OncoC4 will negotiate for the commercialization of therapies in certain territories.
  • OncoC4 will receive $200M up front and is eligible for undisclosed development, regulatory, and commercial milestones, plus tiered double-digit royalties.

Last Month:

Congrats to OncoC4 and BioNTech for landing DealForma’s March 2023 Top Biopharma Deal. Last month’s Deal of the Month was Axsome and Pharmanovia deal for Sunosi. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Biopharma Venture Investment Through Q3 2023

Biopharma Venture Investment Through Q3 2023

Biopharma venture investment totals rebounded in Q3 2023, nearing 2020 quarterly levels. The number of rounds, especially for seed and Series A, are still depressed as we are seeing investors re-investing in later rounds of portfolio companies rather than new...

Biopharma M&A Through Q3 2023

Biopharma M&A Through Q3 2023

This is a quick readout of biopharma M&A activity through Q3 2023 as we track the prominent deals for the year leading up to year-end. Among some of the largest in biopharma are Novo Nordisk's acquisition of Inversago Pharma offering shareholders up to $1.075...

Biopharma R&D Partnerships – Q3 2023 Review

Biopharma R&D Partnerships – Q3 2023 Review

Biotech, pharma, and medtech R&D partnerships in Q3 2023 settled to pre-2020 levels on total deal announced values but again on fewer deals. Major deal announcements in Q3 included Pfizer / Flagship Pioneering, Alnylam / Roche, Nanobiotix / Janssen, Orionis /...